Status:

COMPLETED

Heparin-Induced Thrombocytopenia Registry

Lead Sponsor:

Brigham and Women's Hospital

Collaborating Sponsors:

Tanabe Pharma Corporation

Conditions:

Heparin-Induced Thrombocytopenia

Eligibility:

All Genders

Brief Summary

The purpose of the Heparin Induced Thrombocytopenia Registry is to explore the frequency of heparin-induced thrombocytopenia (HIT) at Brigham and Women's Hospital and to assess its mortality rate. Ret...

Detailed Description

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction with potentially fatal complications of venous and arterial thrombosis. HIT with thrombosis causes prolonged hospita...

Eligibility Criteria

Inclusion

  • All patients hospitalized at BWH who have a PF4-Positive antibody test

Exclusion

    Key Trial Info

    Start Date :

    October 1 2005

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    August 1 2007

    Estimated Enrollment :

    242 Patients enrolled

    Trial Details

    Trial ID

    NCT00456326

    Start Date

    October 1 2005

    End Date

    August 1 2007

    Last Update

    February 18 2008

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Brigham and Women's Hospital

    Boston, Massachusetts, United States, 02115